1. Frangoul, Haydar, Altshuler, David, Cappellini, M Domenica, Yen, Angela, Corbacioglu, Selim. 2020. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. In The New England journal of medicine, 384, 252-260. doi:10.1056/NEJMoa2031054. https://pubmed.ncbi.nlm.nih.gov/33283989/
2. Fu, Bin, Liao, Jiaoyang, Chen, Shuanghong, Liu, Mingyao, Wu, Yuxuan. 2022. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia. In Nature medicine, 28, 1573-1580. doi:10.1038/s41591-022-01906-z. https://pubmed.ncbi.nlm.nih.gov/35922667/
3. Mahmoud Ahmed, Nahil Hassan, Lai, Mei I. . The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment. In Cardiovascular & hematological disorders drug targets, 22, 226-236. doi:10.2174/1871529X23666230123140926. https://pubmed.ncbi.nlm.nih.gov/36734897/
4. Demirci, Selami, Uchida, Naoya, Tisdale, John F. 2018. Gene therapy for sickle cell disease: An update. In Cytotherapy, 20, 899-910. doi:10.1016/j.jcyt.2018.04.003. https://pubmed.ncbi.nlm.nih.gov/29859773/
5. Sankaran, Vijay G, Menne, Tobias F, Xu, Jian, Cantor, Alan B, Orkin, Stuart H. 2008. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. In Science (New York, N.Y.), 322, 1839-42. doi:10.1126/science.1165409. https://pubmed.ncbi.nlm.nih.gov/19056937/
6. Sultan, Iyad, Tbakhi, Abdelghani. 2020. BCL11A gene over-expression in high risk neuroblastoma. In Cancer genetics, 244, 30-31. doi:10.1016/j.cancergen.2020.02.003. https://pubmed.ncbi.nlm.nih.gov/32113148/
智鼠故事 
